-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (01276): The marketing license application for the new indications of hichrapopa ethanolamine tablets was accepted by the State Drug Administration

Zhitongcaijing·11/20/2026 09:17:02
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company received the “Notice of Acceptance” issued by the State Drug Administration, and the company's marketing license application for the new indications of hichipopa ethanolamine tablets was accepted by the State Drug Administration.

This listing is based on a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial (SHR8735-302) evaluating the efficacy and safety of hizripopa ethanolamine tablets in patients with chronic liver disease-related thrombocytopenia who intend to undergo elective invasive surgery. Professor Zhou Jian of Zhongshan Hospital affiliated to Fudan University acted as the main researcher, and 21 domestic centers participated in the study. A total of 127 adult patients with chronic liver disease-related thrombocytopenia who were to be treated with invasive elective surgery were enrolled in the study. In August 2026, the study reached the main research endpoints set by the programme. The study results showed that the test group was significantly superior to the control group in terms of main efficacy endpoints, and had good safety and tolerability, which is expected to provide patients with more treatment options.